Author:
Whicker Margaret E.,Lin Z. Ping,Hanna Ruth,Sartorelli Alan C.,Ratner Elena S.
Funder
National Institute of Child Health and Human Development
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference47 articles.
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin. 2012;62(1):10–29.
2. SEER Cancer Statistics Review, 1975–2010 [Internet]. Bethesda, MD.: National Cancer Institute; based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Available from:
http://seer.cancer.gov/csr/1975_2010/
. Accessed 29 Dec 2013.
3. du Bois A, Lück H, Meier W, Adams H, Möbus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320–9.
4. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699–708.
5. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;34(1):1–6.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献